These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29972745)

  • 81. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
    Jaffe JH; O'Keeffe C
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Maintenance for opioid addiction with buprenorphine and methadone: "The only thing new in the world is the history you don't know".
    Stimmel B
    J Addict Dis; 2005; 24(3):1-6. PubMed ID: 16186079
    [No Abstract]   [Full Text] [Related]  

  • 83. Medicalising the treatment of opioid dependence.
    Peh LH; Ng BY
    Ann Acad Med Singap; 2006 Jul; 35(7):447-9. PubMed ID: 16902718
    [No Abstract]   [Full Text] [Related]  

  • 84. Prescribing Opioid Replacement Therapy in U.S. Correctional Settings.
    Farahmand P; Modesto-Lowe V; Chaplin MM
    J Am Acad Psychiatry Law; 2017 Dec; 45(4):472-477. PubMed ID: 29282239
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Helping 'them': our role in recovery from opioid dependence.
    Loxterkamp D
    Ann Fam Med; 2006; 4(2):168-71. PubMed ID: 16569721
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 87. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
    Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
    Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 89. From the Food and Drug Administration.
    JAMA; 2002 Dec; 288(21):2678. PubMed ID: 12460076
    [No Abstract]   [Full Text] [Related]  

  • 90. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 91. As Overdoses Climb, Emergency Departments Begin Treating Opioid Use Disorder.
    Rubin R
    JAMA; 2018 Jun; 319(21):2158-2160. PubMed ID: 29800009
    [No Abstract]   [Full Text] [Related]  

  • 92. Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice".
    Woody G; Bruce D; Korthuis PT; Chhatre S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Poole S; Metzger D; Ling W
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142-3. PubMed ID: 25243431
    [No Abstract]   [Full Text] [Related]  

  • 93. Methadone vs buprenorphine.
    Byrne A; Hallinan R; Watson R; Wodak A
    Br J Gen Pract; 2005 Jul; 55(516):558-9; author reply 559. PubMed ID: 16004754
    [No Abstract]   [Full Text] [Related]  

  • 94. Opioid Use Disorder and Incarceration - Hope for Ensuring the Continuity of Treatment.
    Binswanger IA
    N Engl J Med; 2019 Mar; 380(13):1193-1195. PubMed ID: 30811904
    [No Abstract]   [Full Text] [Related]  

  • 95. Criminal justice continuum for opioid users at risk of overdose.
    Brinkley-Rubinstein L; Zaller N; Martino S; Cloud DH; McCauley E; Heise A; Seal D
    Addict Behav; 2018 Nov; 86():104-110. PubMed ID: 29544869
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder.
    Salisbury-Afshar E
    Am Fam Physician; 2015 Feb; 91(3):165-6. PubMed ID: 25822268
    [No Abstract]   [Full Text] [Related]  

  • 98. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 99. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

  • 100. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.